---
title: 'Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients
  Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective
  Cohort Study'
date: '2025-01-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39796776/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250111170808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Multimodal treatment, including ch14.18/SP2/0, can achieve
  long-term survival in HR-NB patients, with a substantial proportion of survivors
  reporting better HRQoL compared to the general population. All patients reported
  long-term side effects mostly attributable to chemotherapy and radiotherapy. The
  relatively high prevalence of autoimmune diseases and persistent diarrhea warrants
  additional longitudinal research on individuals treated with anti-GD2 ...'
disable_comments: true
---
CONCLUSIONS: Multimodal treatment, including ch14.18/SP2/0, can achieve long-term survival in HR-NB patients, with a substantial proportion of survivors reporting better HRQoL compared to the general population. All patients reported long-term side effects mostly attributable to chemotherapy and radiotherapy. The relatively high prevalence of autoimmune diseases and persistent diarrhea warrants additional longitudinal research on individuals treated with anti-GD2 ...